Why Britain Can't Build a Trillion Dollar Giant
This week, a single American memory chip company became worth more than AstraZeneca, HSBC and Shell combined. So why has Britain never built one of its own?
Neil Woodford has spent more than 30 years as one of the largest shareholders in some of Britain's biggest companies. He was a top-five holder of GSK for over a decade. He helped see off Pfizer's bid for AstraZeneca. He's sat across from board after board, telling them what they had to do to be worth more. In this episode of The Noise Cancelling Podcast, he tells the story of how Britain keeps building world-class companies and then throws them away.
We cover:
🔹 Why scale isn't the answer (Taiwan built TSMC; South Korea built Samsung and SK Hynix, both worth over $1 trillion)
🔹 The corporate governance trap: why the average FTSE 100 CEO lasts under four years
🔹 BP's third chairman in three years, and what it tells you about UK boards
🔹 The Glaxo (GSK) story: more than fifteen years as a top shareholder, shouted down, sold in frustration in 2017, vindicated five years too late
🔹 AstraZeneca and the 2014 Pfizer bid at £55 — and what's happened to the share price since
🔹 The three things Neil looks for to separate businesses that compound from businesses that waste themselves
🔹 Why Simon Wolfson at Next is the gold standard of British corporate leadership
🔹 How Micron earned its place in Neil's AI picks and shovels thesis
🔹 Whether Britain can ever produce its own trillion dollar company
The Noise Cancelling Podcast is a weekly show with Neil Woodford and Jon Adair. Each week we take a piece of confusion in the financial press, teach the mechanism behind it, and give Neil's specific view on what it means for investors.
If you got something from this, please subscribe. It helps the channel more than you'd think. And leave a comment below with the British company you reckon should have been a global giant but never made it.
Important: Nothing in this video is investment advice. Companies are discussed for educational purposes only. You should consult a regulated financial adviser before making any investment decision.
#NeilWoodford #UKStocks #Investing #FTSE100 #StockMarket
More episodes
Why Neil Woodford Won’t Buy the Anthropic IPO
The Anthropic IPO is weeks away, and its filing shows a business like no other: $17bn of sales in three months, still a loss, and $895bn signed away on computing power. Neil Woodford goes through the numbers and asks who actually keeps the profit from AI.
Show notesBritain Can Grow Its Way Out of This Budget
Budget 2026 raised the tax on your savings and rental income, on top of a rise already due in April, and the Chancellor barely mentioned it. Neil Woodford explains why John Healey did it, and why he thinks the official forecast that says more tax rises are coming is wrong.
Show notesThe AI Boom Is Only in the Foothills
AI stocks sold off hard last week, and the Financial Times called it a dress rehearsal for an AI reckoning. Is the AI bubble about to burst? Neil Woodford thinks the AI boom is only in the foothills, but he has a clear view on who is holding the risk if it doesn’t pay for itself.
Show notesGo deeper than the podcast
Access the strategies, research, and real-time portfolio data behind the conversations.
